Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

Mycobacterial cell wall–DNA complex (MCC) is an effective treatment modality for bladder cancer, and has a favorable safety profile when compared with intravesical therapy using live bacillus ...

J&J is developing a second Taris-derived candidate called TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), and has predicted that peak sales of the two ...

Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the ...

If approved, TAR-200 will be the first intravesical drug-releasing system in the given indication. The FDA will review this submission under its Real-Time Oncology Review (“RTOR”) program.

Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment ...

To guide the management of ketamine-induced uropathy, the French Association of Urology (AFU) recently recommended treatments, such as oral pentosan polysulfate (Elmiron) and intravesical ...